The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Among women with gestational diabetes, the use of real-time continuous glucose monitoring (rt-CGM) is associated with a lower incidence of large-for-gestational-age (LGA) infants and reduced ...

Withdrawal of tirzepatide treatment in adults with obesity who have achieved initial weight loss is associated with substantial weight regain and a corresponding reversal of the positive ...

Topline data were announced from a phase 3 trial evaluating ersodetug in patients aged 3 months to 45 years with congenital hyperinsulinism.

Higher body dissatisfaction was linked to more severe eating disorder, depressive symptoms in monozygotic and dizygotic twin difference analyses. HealthDay News — Body dissatisfaction may causally ...

The FDA approved Lerochol, a monthly PCSK9 inhibitor, for adults with hypercholesterolemia to reduce LDL-C levels alongside diet and exercise.

Giredestrant shows significant improvement in iDFS in patients with early-stage, HR-positive, HER2-negative breast cancer.

Planned early-term birth based on risk stratification for preeclampsia reduces preeclampsia incidence, without an increase in complications.

Sports injuries do not occur more often during menstruation, but those sustained during menstruation have a significantly higher burden.

Type 1 diabetes mellitus is an autoimmune disorder in which the immune system attacks the insulin-producing beta cells of the pancreas so the pancreas cannot produce insulin. The exact etiology of ...

Credit: Getty Images With the FDA approval of Zepbound (tirzepatide) for obstructive sleep apnea, GLP-1 receptor agonists harbor potential beyond weight and diabetes management. In recent years, ...